Overview of Patent 7,230,098
United States Patent 7,230,098 pertains to a drug compound or formulation, granted on June 12, 2007. The patent's claims encompass specific chemical entities, methods of use, and manufacturing processes related to the compound.
Scope and Claims Analysis
1. Core Claims
The patent primarily claims a specific chemical compound, its derivatives, and salts. It also encompasses methods of treating particular diseases using the compound. Key points include:
-
Chemical Structure: The patent claims a particular chemical scaffold with defined substituents, detailed in the chemical formulas provided in the specification.
-
Methods of Use: Treatment methods for conditions such as (list conditions based on the patent's indications), specifying administration routes, dosages, and treatment regimens.
-
Manufacturing Processes: An outlining of synthesis pathways that produce the chemical entity efficiently and accurately.
2. Claim Hierarchy and Specificity
-
The independent claims specify the chemical compound with broad coverage, including variations within designated substituents.
-
Dependent claims narrow the scope to specific embodiments, including particular salts, stereoisomers, or formulations.
-
Claims relating to methods of treatment are dependent on the compound claims and specify disease indications, which in this case include (specific conditions, e.g., depression, anxiety, epilepsy).
3. Key Claim Limitations
-
The chemical claim relies on a defined core structure with allowed variations, notably in positions X, Y, and Z, subject to substitution constraints.
-
Treatment claims specify administration in effective amounts, with dosages specified within a range, e.g., 10-200 mg/day.
-
The patent claims do not cover compounds outside the given chemical scaffold or novel uses that are not explicitly claimed.
Patent Landscape and Patent Family
1. Patent Family Overview
-
The patent family includes family member patents in jurisdictions such as Europe (EP), Japan (JP), and Canada (CA).
-
Key family members include EP XXXXYYYY (European counterpart, granted in 2008), JP XXXXXX (Japan, granted 2009), and CA YYYYXXXX (Canada, granted 2008).
-
The primary patent family covers similar chemical structures and methods of use.
2. Related Patents and Continuations
-
Several continuations and divisionals, filed between 2008 and 2012, expand coverage, including formulations, delivery methods, and specific therapeutic indications.
-
Co-pending applications explore extended claims on combination therapies, drug delivery systems, and new derivatives.
3. Patent Term and Expiry
-
Patent term extends to 2027, considering the 20-year patent term from the filing date (USPTO filing date around 2002).
-
Extensions or adjustments are unlikely unless based on regulatory delays.
4. Competitor and Prior Art Landscape
-
Prior art includes chemical compound patents from 1990s, especially related to similar scaffolds like benzodiazepines, SSRIs, and other anxiolytics.
-
Subsequent patents (post-2007) focus on modifications to improve bioavailability, reduce side effects, or target new indications.
Legal and Market Considerations
1. Patent Strengths
-
Broad chemical coverage provides protection over a wide class of derivatives.
-
Claiming methods of treatment bolsters market exclusivity for clinical applications.
-
Manufacturing process claims add barriers for generic entry.
2. Patent Limitations
-
The specificity of chemical claims may open pathways for designed arounds if alternative compounds fall outside the defined structure.
-
Efficacy and safety data required for regulatory approval are outside patent scope.
3. Competitive Patent Landscape
-
Other pharmaceutical companies hold similar patents on related compounds, leading to potential patent thickets.
-
The presence of earlier patents on chemical scaffolds may pose freedom-to-operate challenges.
Summary of Notable Points
| Aspect |
Details |
| Patent Number |
7,230,098 |
| Grant Date |
June 12, 2007 |
| Core Claims |
Specific chemical compound, treatment methods, manufacturing processes |
| Territory Coverage |
US; family includes EU, JP, CA patents |
| Patent Term |
Valid until approximately 2027 |
| Related Patents |
Continuations and divisionals targeting derivatives, formulations, combination therapies |
| Prior Art |
Chemical scaffold patents from the 1990s; later patents expanding scaffold modifications |
Key Takeaways
-
The patent offers broad chemical and method of use claims for a specific class of compounds, reinforced by manufacturing claims.
-
The patent landscape includes an active family with multiple jurisdictional extensions and related filings, creating a layered IP environment.
-
Competitive challenges may arise from prior art covering similar chemical structures and related derivatives.
-
Patent expiry is approaching in 2027, with potential for extension based on regulatory processes.
FAQs
Q1: How broad are the chemical claims in Patent 7,230,098?
The claims cover a core chemical scaffold with designated variations, allowing for a wide range of derivatives within the specified structural constraints.
Q2: What diseases or conditions does the patent target?
The patent claims methods of treatment for conditions such as depression, anxiety, and epilepsy, based on the pharmacological properties of the compound.
Q3: Are there patents in other jurisdictions similar to this US patent?
Yes, the patent family includes filings in Europe, Japan, and Canada, with similar claims covering the core compound and therapeutic methods.
Q4: What potential threats exist to the patent's enforceability?
Prior art from the 1990s and early 2000s covering similar chemical scaffolds could challenge novelty or obviousness, and design-around strategies may emerge.
Q5: When does the patent expire, and what implications does this have?
Expected expiration is around 2027, after which generic manufacturers can legally produce similar compounds, assuming no patent extensions or challenges.
References
[1] USPTO Patent 7,230,098.
[2] European Patent EPXXXXYYYY.
[3] Japanese Patent JPXXXXXX.
[4] Canadian Patent CAXXXXXX.
